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Abstract
While there is a growing literature on the clinical performance of VIA in HIV-infected women, to
our knowledge none have studied VIA enhanced by digital cervicography. We estimated clinical
performance of cervicography and cytology to detect cervical intraepithelial neoplasia grade 2 or
worse. Sensitivity and specificity of cervicography were 84% (95% confidence interval [CI]:
72%–91%) and 58% (95%CI: 52%–64%). At the high-grade squamous intraepithelial lesion or
worse cutoff for cytology, sensitivity and specificity were 61% (95%CI: 48%–72%) and 58%
(95%CI: 52%–64%). In our study, cervicography appears to be as good as cytology in HIV-
infected women.
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Cervical cytology has helped reduce cervical cancer mortality in the developed world,1,2 but
the lack of trained personnel and limited laboratory and patient-recall infrastructure has
hindered implementation of cytology-based screening in much of the developing world.
Visual inspection with acetic acid (VIA) is a low-cost alternative that can be performed by
non-physician health providers, and has become a popular screening option in resource-
constrained countries.3
HIV-infected women in developing countries are a high-risk group for cervical cancer,
particularly with longer life spans on affordable antiretroviral therapy, but generally have
little or no access to quality cervical cancer screening services.4,5 Cytology and VIA-based
screening have been compared in several studies,6,7 but few have focused on HIV-infected
women,8–10 and none of the studies in HIV-infected women have evaluated VIA enhanced
by digital cervicography (DC). DC is an adjunct to VIA and involves digital photography of
the cervix, using a commercial brand camera, to allow for magnified visualization of surface
morphology, while also facilitating telemedicine support, patient and provider education,
and quality assurance of screening.11
Zambia has a particularly high burden of cervical cancer, with the second-highest incidence
and highest mortality rates in the world.1,2 The Cervical Cancer Prevention Program in
Zambia (CCPPZ), a public-sector initiative, offers nurse-led services with DC with same-
day cryotherapy for eligible precancerous lesions, or referral for loop electrosurgical
excision procedure (LEEP) treatment for cryotherapy-ineligible lesions.12,13 Surgical,
radiation, and chemotherapy services for management of invasive cervical cancer are
offered through Zambian Ministry of Health facilities.
To assess the clinical performance of DC, a resource-appropriate screening technology, as
well as cytology in HIV-infected women, we enrolled HIV-infected women in Zambia and
calculated the clinical performance of each screening test to detect cervical lesions on
histopathology.
METHODS
Participants were enrolled between January 2008 and December 2011 from Matero public
health clinic in Lusaka. After counseling by a nurse provider, HIV-infected women were
invited to participate in the study if they were non-pregnant by self-report, between 20–45
years of age, and deemed healthy enough to undergo a pelvic examination (assessed by the
nurse enrolling for the study and defined as patients who were not bedridden or physically
incapacitated and were mobile enough to undergo a pelvic exam without discomfort).
Informed consent was obtained from all participants, and a nurse-administered questionnaire
was used to collect socio-demographic data.
Trained, experienced nurses performed the study procedures, starting with the collection of
cervical specimens for thin layer cytology using a cytobrush (for endocervical sampling) and
an Ayres spatula (for ectocervical sampling). Both the cytobrush and spatula were rinsed in
PreservCyt™ vials (Cytyc™ Corporation, Marlborough, MA, USA) and stored at room
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temperature locally for <4 weeks before batched-shipping to a U.S.-based laboratory for
processing, analysis and interpretation by a certified senior cytotechnologist according to the
revised (2001) Bethesda classification system. All abnormal slides and 10% of normals were
subsequently reviewed by a board certified senior cytopathologist.
Immediately after the collection for cytology, the nurse conducted VIA enhanced by DC,
performed by washing the cervix with 5% acetic acid, waiting for 2–3 minutes, and
evaluating acetowhite lesions by real-time digital imaging of the cervix.11 To capture the
DC images, the study nurse used a 7–8 megapixel digital camera with 10x optical zoom and
a built-in flash. The image was reviewed in real-time, and the results of the DC were
recorded as being positive or negative. Next, the nurse performed DC-directed cervical
punch biopsies with a 2×4mm tip Tischler biopsy forceps. A biopsy was taken from the
lesion that appeared to have the most advanced degree of neoplasia, and from a normal
appearing area of the cervical transformation zone. If the cervix had no abnormal area, only
a normal area biopsy was taken of the transformation zone; conversely, if the cervix had no
normal area, only an abnormal area biopsy was taken. Biopsy specimens were immediately
placed in 10% formalin and sent to the pathology department of the University Teaching
Hospital in Lusaka, Zambia for review by a United Kingdom-trained, board-certified
Zambian senior pathologist. A combined histopathology variable was created to represent
the most severe diagnosis from the normal and abnormal areas for each woman.
Patients with cervical intraepithelial neoplasia (CIN) grades 2 or 3 on biopsy underwent
therapeutic LEEP. Women with evidence of invasive cancer on biopsy were immediately
referred to the University Teaching Hospital (UTH) in Lusaka for further management.
Clinical and pathology data were entered into a Microsoft Access™ (Redmond, WA, USA)
database and cleaned using Microsoft Excel™ and SAS™ version 9.2 (SAS Institute Inc.,
Cary, NC, USA). SAS and Open Epi (www.openepi.com) were used to calculate the point
estimates and 95% confidence intervals (95% CI) of sensitivity, specificity, positive
predictive value (PPV), and negative predictive value (NPV) of DC and cytology. DC
results were dichotomized as positive and negative, while cytology results were
dichotomized at three clinically-relevant cut-offs: atypical squamous cells of undetermined
significance or worse (ASC-US+), low-grade squamous intraepithelial lesions or worse
(LSIL+), or high-grade squamous intraepithelial lesions or worse (HSIL+).
Ethical approval for this study was obtained from the University of Zambia Biomedical
Research Ethics Committee and the University of Alabama at Birmingham Institutional
Review Board (affiliation of CIDRZ at the time of this study).
RESULTS
We enrolled 303 women into the study; all women were screened by both cytology and DC,
and had histopathology results from a punch biopsy. The median age was 32 years, 10.6%
had completed high school, and 61.8% were married (Table 1). A total of 86.4% were
antiretroviral-experienced, and 56.5% had a baseline CD4+ count <200 cells/mm3.
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Half of all women (50.5%) screened positive by DC, and nearly half (45.5%) of all women
had HSIL+ (Table 1). Using the most severe histopathologic diagnosis from the individual
biopsy results for each woman, 63.7% of women had CIN1 or worse (CIN1+), 20.1% had
CIN2+, and 10.9% had CIN3+ lesions (Table 1).
The sensitivity of DC for identifying CIN2+ was 84% (95% CI: 72% – 91%) and the
specificity was 58% (95% CI: 52% – 64%) (Table 2). The sensitivity estimates of cytology
for identifying CIN2+ were as follows: HSIL+, 61% (95% CI: 48% – 72%); LSIL+, 90%
(95% CI: 80% – 95%); ASC-US+, 100% (95% CI: 94% – 100%). The specificity estimates
of cytology for identifying CIN2+ were: HSIL+, 58% (95% CI: 52% – 64%); LSIL+, 35%
(95% CI: 29% – 41%); ASC-US+, 13% (95% CI: 10% – 18%). The PPVs were low (23% –
33%) for both tests, while the NPVs were correspondingly high (86% – 100%). A similar
pattern of results was observed at the CIN3+ diagnostic threshold on histopathology (Table
2).
DISCUSSION
We have demonstrated that among HIV-infected women in Zambia, the point estimates for
sensitivity of DC to detect CIN2+ and CIN3+ lesions were higher than those of cytology at
the HSIL+ cutoff. While previous studies have reported that VIA has higher sensitivity than
cytology for both HIV-uninfected women6,7 and HIV-infected women,8–10 our study is the
first to provide estimates of the clinical performance of DC.
The sensitivity point estimate of DC for CIN2+ that we report (84%) is slightly higher than
three previous studies of HIV-infected women that reported 65% – 80% sensitivity for
unaided VIA.8–10 The specificity point estimate of DC for CIN2+ that we report (58%) lies
near the lower end of the range (51% – 83%) reported for unaided VIA in these studies.8–10
The specificity point estimate of cytology for CIN2+ that we report (58%) is slightly lower
but comparable to that of Mabeya et al. (66%),9 while both are substantially lower than that
reported by Sahasrabuddhe et al. (83%).8 Our lower specificity of cytology could be because
our histopathology gold standard was based solely on punch biopsy specimens. Punch
biopsies are small, and in women who screen DC positive the punch biopsies could lead to
under-ascertainment of the true amount of cervical disease if the lesion is not adequately
sampled in the (relatively small) punch biopsy specimen. Our histopathology specimens, and
that of Mabeya et al., were from punch biopsy alone, while those of Sahasrabuddhe et al.
were based on real-time colposcopically-guided cervical punch biopsies, endocervical
curettage, and LEEP, which result in a more extensive sampling of at-risk areas on the
cervix.
Strengths of our study include the number of women enrolled, leading to relatively precise
estimates of test performance characteristics. In addition, all women had a punch biopsy
taken, and while biopsy placement was guided by DC impression, biopsies were also
obtained from normal appearing areas of the cervix. Thus, histopathology was obtained
regardless of DC or cytology test results, and we have minimized (if not eliminated) any
verification bias that can result from only performing histopathology on screen-positive
women.
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Our clinical performance point estimates suggest that DC is as good as or better than
cytology for identifying cervical lesions in our population of HIV-infected women, while the
relatively lower specificity point estimate of DC (58%) likely leads to overtreatment and/or
over-referral of women who, based on the CCPPZ clinical protocol, require excisional
biopsy (LEEP) or diagnostic biopsy. The program scale-up in CCPPZ has used the
advantage of the reasonably high sensitivity of DC,14 while overtreatment with cryotherapy
is a lesser concern because this treatment modality has been shown to be a safe and
acceptable treatment method.15 Nevertheless, the integration of other screening tests, such as
point-of-care human papillomavirus DNA or E6 tests, either individually or in combination
with DC, may improve both the sensitivity and specificity of cervical cancer screening in
HIV-infected women, and thus merit investigation.
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